International AIDS Society

Track B - Clinical Sciences

Natural History of HIV Disease

B1 Staging, progression of disease: impact of co-factors / viral clade / tropism / genetic factors/ gender/age/ coinfection
B2 Acute and early infection
B3 HIV disease burden: morbidity/mortality/ impact on life expectancy
B4 Pre- HAART interventions: impact on disease progression (i.e. role of nutrition or supplements, antivirals, etc.)

Diagnosis and Monitoring Tools

B5 New monitoring strategies including rapid and point of care tests
B6 Viral resistance testing in clinical trials and practice
B7 Viral tropism

HIV-Associated Conditions

B8 HIV associated opportunistic infections (excluding tuberculosis)
B9 Tuberculosis
B10 Other bacterial infections malaria and parasitic infections
B11 Hepatitis B and D
B12 Hepatitis C
B13 Sexually transmitted infections (STI) excluding HPV
B14 HPV (men and women) diagnosis, therapy, prevention, monitoring, anal and cervical cancer
B15 Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis, co-trimoxazole prophylaxis and IPT
B16 Immune reconstitution disorders / IRIS
B17 AIDS related malignancies (KS, lymphoma,) including HHV8 infection
B18 Non-AIDS related malignancies

Antiretroviral Therapies in Adults  (Strategic Categories Apply to Resource Rich and Constrained Settings)

B19 Clinical trials - phase I/II
B20 Clinical trials - phase III/post-licensing
B21 Acute and early infection including management of patients with acquired viral resistance
B22 Pharmacology, pharmacokinetics, pharmacogenomics, role of therapeutic drug monitoring, drug interactions
B23 Adherence
B24 When to start therapy
B25 Treatment strategies for first line therapy including management of late presenters
B26 Simplification strategies (induction/maintenance, fixed dose combinations, bPI monotherapy and NRTI-sparing regimens)
B27 Switch strategies 
B28 Management strategies for treatment experienced patients

Specific Issues Related to HIV Infection in Women

B29 Pharmacokinetics and outcomes of ARV in women during and after pregnancy including option B+
B30 Non-pregnant women including menopause, contraception

HIV Management  in Children

B31 Diagnosis of HIV disease including early diagnosis in infancy
B32 HIV exposed uninfected children
B33 Pharmacology, pharmacokinetics, drug formulations
B34 Clinical trials and antiretroviral therapy for children
B35 Cohort studies of HIV- and ARV-related issues in children
B36 Adherence
B37 Complications of HIV and its therapy  including impact on growth, development and neurocognition
B38 Opportunistic infections, non-HIV related infections and malnutrition

HIV Management in Adolescents

B39 ARV therapy: clinical trials in first and subsequent lines
B40 ARV management strategies – cohort studies
B41 Behaviour health outcomes including sexual risks, substance use and poor adherence
B42 Mental health and neurocognition
B43 Complications of therapy and comorbidity
B44 HIV associated infections and malignancies
B45 Transitioning care

Comorbidity and  Complications of Therapy in Adults  (Prevalence, Prevention and Management)

B46 Fat accumulation and lipoatrophy
B47 Cardiovascular disease (including lipid abnormalities hypertension and smoking)
B48 Bone disease
B49 Renal disease
B50 Endocrine and metabolic issues (glucose, vitamin D, testosterone)
B51 Liver complications - hepatosteatosis
B52 HIV associated neurocognitive disorders (HAND) and other neurologic disorders
B53 Depression and other psychiatric manifestations
B54 Other adverse reactions and complications of ARV therapy
B55 HIV aging and frailty

Other Strategies and Therapies

B56 Therapeutic vaccine and immune based therapy trials
B57 Complementary and traditional medicines
B58 Strategies for eradication / reservoir depletion

Back to categories